BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/12/2023 10:39:02 AM | Browse: 275 | Download: 967
 |
Received |
|
2023-06-07 19:02 |
|
Peer-Review Started |
|
2023-06-07 19:03 |
|
First Decision by Editorial Office Director |
|
2023-07-07 09:04 |
|
Return for Revision |
|
2023-07-07 09:04 |
|
Revised |
|
2023-07-21 19:57 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-07-26 02:55 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-07-27 00:39 |
|
Articles in Press |
|
2023-07-27 00:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-27 08:26 |
|
Publish the Manuscript Online |
|
2023-10-12 10:39 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Silvana Ancona, Sara Signa, Chiara Longo, Giuliana Cangemi, Roberta Carfora, Enrico Drago, Alessandro La Rosa, Marco Crocco, Andrea Chiaro, Paolo Gandullia and Serena Arrigo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Serena Arrigo, MD, Pediatric Gastroenterology and Endoscopy Unit, IRCCS Istituto Giannina Gaslini, 5 Via Gerolamo Gaslini, Genova 16147, Italy. serenaarrigo@gaslini.org |
| Key Words |
Infantile-onset inflammatory bowel disease; Adalimumab; Loss of response; Dose escalation; Anti-drug antibodies; Case report |
| Core Tip |
Infantile-onset inflammatory bowel disease (IBD) frequently has a more severe course and a greater resistance to standard therapy than IBD in older children. Anti-tumor necrosis factor agents often lead to the production of anti-drug antibodies, resulting in loss of clinical response and disease progression. For this reason, the early detection of anti-drug antibodies is important, which may be possible with therapeutic drug monitoring. To date, commonly used strategies to overcome anti-drug antibodies are switching drugs or adding an immunomodulator, but a better option may be dose escalation. |
| Publish Date |
2023-10-12 10:39 |
| Citation |
Ancona S, Signa S, Longo C, Cangemi G, Carfora R, Drago E, La Rosa A, Crocco M, Chiaro A, Gandullia P, Arrigo S. Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease. World J Gastroenterol 2023; 29(38): 5428-5434 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i38/5428.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i38.5428 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
